BeOne Medicines (NASDAQ:ONC) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen lowered shares of BeOne Medicines (NASDAQ:ONC) from a strong-buy rating to a buy rating in a research note released on Saturday morning.

A number of other research analysts have also weighed in on ONC. Barclays raised their price objective on BeOne Medicines from $394.00 to $405.00 and gave the company an “overweight” rating in a report on Friday. Royal Bank Of Canada increased their target price on shares of BeOne Medicines from $417.00 to $425.00 and gave the company an “outperform” rating in a research report on Thursday. Truist Financial raised their price target on shares of BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday. Citizens Jmp boosted their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Finally, Guggenheim increased their price objective on shares of BeOne Medicines from $400.00 to $410.00 and gave the company a “buy” rating in a report on Friday. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $394.25.

BeOne Medicines Trading Down 1.7%

ONC stock opened at $316.99 on Friday. BeOne Medicines has a 12-month low of $196.45 and a 12-month high of $385.22. The business’s 50-day moving average is $336.81 and its 200 day moving average is $330.70. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The stock has a market cap of $34.76 billion, a price-to-earnings ratio of 125.79 and a beta of 0.52.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 11.10%. On average, sell-side analysts anticipate that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO John Oyler sold 24,369 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $302.87, for a total value of $7,380,639.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Chan Henry Lee sold 1,660 shares of BeOne Medicines stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. The SEC filing for this sale provides additional information. Insiders have sold a total of 102,656 shares of company stock valued at $31,567,496 in the last 90 days. Insiders own 6.62% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. EFG International AG acquired a new stake in shares of BeOne Medicines during the fourth quarter valued at about $25,000. Anchor Investment Management LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $26,000. Leonteq Securities AG acquired a new stake in BeOne Medicines in the 4th quarter valued at approximately $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines in the 2nd quarter valued at approximately $35,000. Finally, CWM LLC raised its position in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.